SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients
Opdivo (nivolumab) now recommended to treat Scottish NHS patients with advanced skin cancer.
The Scottish Medicines Consortium (SMC) has now recommended Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) to treat Scottish NHS patients with advanced skin cancer. The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access in Scotland on par with the rest of the UK. This potentially life-extending treatment option will be made available for previously-untreated adult patients with advanced (unresectable or metastatic) melanoma. The incidence of melanoma in Scotland has risen by 30% over the last 10 years – a rate higher than any other common cancer, including the country’s biggest cancer killer, lung cancer.
“Today’s decision will be welcomed by clinicians in Scotland; it means that we can now offer our patients this exciting new medicine. Our understanding of the science of tumour cells continues to advance and has resulted in immunotherapy medicines, such as nivolumab, that are changing the way that we treat advanced skin cancer. Nivolumab has demonstrated its potential to increase survival rates in this devastating disease, which is the ultimate goal of treatment for clinicians, patients and their families,” said Professor Jeff Evans, Director of Institute of Cancer Sciences and Professor of Translational Cancer Research at the University of Glasgow.
Nivolumab has an innovative mode of action that works by harnessing the ability of the immune system to fight advanced (metastatic or unresectable) skin cancer. It has been shown to significantly improve survival in this disease compared to chemotherapy, regardless of whether a patient has received prior treatment or not.
“Until today, we have seen an untenable situation where patients in England and Wales had access to this medicine, while those in Scotland did not,” said Gillian Nuttall, Founder, Melanoma UK. “I am delighted that today’s decision will bring new hope for patients who have been waiting for access to this medicine. I’m pleased that all parties have worked together to come to a solution for patients on this occasion, but to prevent this type of disparity continuing to affect patients in future, it is important that we work towards implementation of a more equitable medicines review process across the UK.”
The decision from the SMC is based on two pivotal Phase III trials (Checkmate -066 and -067). Data from Checkmate -066 have shown significantly more previously-untreated BRAF wild-type patients who received nivolumab were still alive at one year (72.9%), compared with those treated with the chemotherapy dacarbazine (42.1%). Furthermore, in study Checkmate -067 patients with previously untreated advanced melanoma, median progression-free survival was 6.9 months for those treated with nivolumab compared with 2.9 months in those receiving ipilimumab.
Data have also demonstrated that previously-untreated patients who received nivolumab experienced fewer serious (grade 3-4) treatment-related adverse events compared with chemotherapy (13% of patients treated with nivolumab vs. 17% of those treated with chemotherapy.
“Nivolumab is a game-changing medicine and we are delighted that NHS patients in Scotland will now have it available as a treatment option for advanced skin cancer.” said Benjamin Hickey, General Manager, UK and Ireland, BMS. “Today’s decision follows the recent SMC decision to recommend nivolumab for advanced squamous lung cancer, making the SMC the first UK reimbursement authority to recognise the value of nivolumab to patients in different cancer types. We remain committed to bringing Scottish patients rapid access to nivolumab in its additional licensed indications.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance